1.	Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 206OC202, 2007-000509-31, NCT00635193
2.	Phase II Study of Volociximab in Patients With Metastatic Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0409104-01, AGENNIX-PDL-M200-1204, PDL-M200-1204, NCT00100685
3.	Phase II Study of Volociximab and Erlotinib Hydrochloride in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0504066-01, PDL-M200-1206, NCT00278187
4.	A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M200-1205, NCT00401570
5.	A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: M200-1211, 2007-003396-39, NCT00654758